Authors acknowledge that larger studies should be conducted to clarify which subsets of patients with SSc have an upregulation of CD30 for a better understanding of the mechanism of action and to select those who could get a greater benefit from directed therapies. The gene discussed is TNFRSF8; the disease is systemic sclerosis.